BIOAF
vs
S&P 500
BIOAF
S&P 500
Over the past 12 months, BIOAF has significantly outperformed S&P 500, delivering a return of +100% compared to the S&P 500's +14% growth.
Stocks Performance
BIOAF vs S&P 500
Performance Gap
BIOAF vs S&P 500
Performance By Year
BIOAF vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
biOasis Technologies Inc
Glance View
biOasis Technologies, Inc. operates as a biopharmaceutical company. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2007-07-24. The firm is engaged in the development of the xB3 platform, a technology for the delivery of therapeutics across the blood brain barrier (BBB) and the treatment of central nervous system (CNS) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. xB3 is based on a human transport protein found circulating at low levels in the blood. The xB3 platform has an efficacy in its ability to shuttle molecules across the blood-brain barrier and reach its targets within the brain through a process called receptor-mediated transcytosis. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
